Table 3.
Association between clinicopathological variables and serum HER2 extracellular domain concentrations n (%)
| Variables |
Serum HER2 ECD concentrations |
P value | |
| > 24.75 ng/mL (n = 36) | ≤ 24.75 ng/mL (n = 203) | ||
| Age (yr) | 0.474 | ||
| ≥ 60 | 17 (47.2) | 109 (53.7) | |
| < 60 | 19 (52.8) | 94 (46.3) | |
| Gender | 0.396 | ||
| Male | 23 (63.9) | 144 (70.9) | |
| Female | 13 (36.1) | 59 (29.1) | |
| Smoking status | 0.452 | ||
| Never | 11 (30.6) | 50 (24.6) | |
| Ever | 25 (69.4) | 153 (75.4) | |
| Tumor location | 0.573 | ||
| GEJ | 5 (13.9) | 36 (17.7) | |
| Non-GEJ | 31 (86.1) | 167 (82.3) | |
| Tumor size | < 0.001 | ||
| ≥ 5 cm | 27 (75.0) | 75 (36.9) | |
| < 5 cm | 9 (25.0) | 128 (63.1) | |
| Type of gastrectomy | 0.266 | ||
| Total | 21 (58.3) | 98 (48.3) | |
| Subtotal | 15 (41.7) | 105 (51.7) | |
| Type of surgery | 0.730 | ||
| Open | 25 (69.4) | 135 (66.5) | |
| MIS | 11 (30.6) | 68 (33.5) | |
| Lymph node involvement | 0.419 | ||
| Positive | 22 (61.1) | 138 (68.0) | |
| Negative | 14 (38.9) | 65 (32.0) | |
| pTNM stage | 0.576 | ||
| I | 6 (16.7) | 33 (16.3) | |
| II | 12 (33.3) | 66 (32.5) | |
| III | 13 (36.1) | 89 (43.8) | |
| IV | 5 (13.9) | 15 (7.4) | |
| Lauren classification | 0.021 | ||
| Intestinal type | 22 (61.1) | 82 (40.4) | |
| Diffuse type | 14 (38.9) | 121 (59.6) | |
| Tissue HER2 status (IHC/FISH) | < 0.001 | ||
| Positive | 21 (58.3) | 18 (8.9) | |
| Negative | 15 (41.7) | 185 (91.1) | |
GEJ: Gastroesophageal junction; HER2: Human epidermal growth factor receptor-2; ECD: Extracellular domain; MIS: Minimally invasive surgery; IHC: Immunohistochemistry; FISH: Fluorescence in situ hybridization.